Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Santarus PPI could be future Merck switch

This article was originally published in The Tan Sheet

Executive Summary

Merck's Schering-Plough consumer products unit would have OTC switch rights to a Santarus dual-buffer prescription proton pump inhibitor if FDA approves it under the Zegerid brand. The agency approved Santarus' immediate-release omeprazole/sodium bicarbonate/magnesium hydroxide prescription drug for treatment of heartburn and other symptoms of gastroesophageal reflex disease in 20-mg and 40-mg doses, the San Diego firm said Dec. 4. If FDA approves a new drug application supplement requesting the drug's name include the Zegerid brand, as Santarus expects, Merck can apply to switch it to OTC, a Santarus spokeswoman said. The Rx announcement follows FDA's approval of Zegerid OTC, set to launch in 2010 (1"The Tan Sheet" Dec. 7, 2009)

You may also be interested in...

Zegerid OTC Approved, Limited To Touting Dual-Ingredient Formula For Now

Merck's Schering-Plough Consumer HealthCare Products division will launchZegerid OTC in the first half of 2010 as the first dual-ingredient OTC proton pump inhibitor

Eyeing Early Chronic Disease Detection Through AI-Based Retinal Scans

South Korean start-up Mediwhale is using AI-guided retinal scans to predict the risk of eye, cardiovascular and kidney diseases. The company has moved ahead of a small pack of competitors and gained regulatory approval and market access in eight territories through a focus on gathering strong evidence to support algorithms.

Shared Savings Legislation Could Increase Medicare Biosimilar Access

Congressman Richard Hudson has introduced US legislation calling for a three-year ‘demonstration project’ into a shared savings payment scheme for biosimilar medicines provided through Medicare Part B.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts